Skip to main content
. 2019 Aug 16;6(5):e603. doi: 10.1212/NXI.0000000000000603

Figure 2. Microphotographs of binding assays of patients' sera to murine teased fibers.

Figure 2

Nodal binding is marked with arrows, and paranodal binding with asterisks. Serum of patient 1 clearly binds to the nodal and paranodal regions at the onset of disease (A). Paranodal binding becomes more prominent during the course of disease (B). Patient 2 binds to the nodes stronger than to the paranodes (C and D), but paranodal binding becomes stronger during the course of disease (D). Patient 3 mainly binds to the nodal region (E), whereas patients 4 and 5 with anti-NF-155 autoantibodies bind to the paranodes only (F and G). Patient 6 weakly binds to the paranodes (H). A normal control does not show any binding (I), and the commercial anti–pan-NF control antibody clearly binds to the nodes and paranodes (J). Bar = 10 μm. NF = neurofascin.